Changchun Genescience Pharmaceutical Co., Ltd.
Clinical trials sponsored by Changchun Genescience Pharmaceutical Co., Ltd., explained in plain language.
-
Experimental antibody targets Hard-to-Treat leukemia, but early trial halted
Disease control TerminatedThis early-phase study tested a new drug called gentulizumab in 58 adults with acute myeloid leukemia or myelodysplastic syndrome that had come back or stopped responding to treatment. The drug works by blocking a protein on cancer cells to help the immune system attack them. The…
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 17, 2026 02:57 UTC
-
New oral test could replace painful insulin injections for hormone diagnosis
Diagnosis TerminatedThis study tested a new oral drink (GS3-007a) to diagnose adult growth hormone deficiency (AGHD). It compared the drink to the standard insulin tolerance test in 120 adults suspected of having AGHD and healthy volunteers. The goal was to see if the oral test works as well as the …
Phase: PHASE2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Diagnosis
Last updated Jun 17, 2026 02:57 UTC